The booming market for unauthorized knockoffs of blockbuster weight-loss drugs could slash future pharmaceutical research and development investment by between $9.3 billion and $11.8 billion, potentially preventing four to five new medicines from being developed, according to a new brief published June 11, 2026 by the Pacific Research Institute. The study warns that compounded versions of GLP-1 drugs—marketed outside FDA safeguards—are creating serious patient safety risks while threatening the financial incentives needed to fuel future medical breakthroughs.
The brief examines the rapid growth of compounded GLP-1 drugs following FDA-declared shortages that began in 2022. Between 8 and 10 percent of U.S. adults are now taking GLP-1 medications—upwards of 34 million Americans—making drugs like semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) among the most widely used diabetes and weight loss treatments. Although the shortages ended in 2025, many compounders continue marketing unauthorized knockoffs. The FDA has linked compounded semaglutide and tirzepatide to hundreds of adverse health events, including hospitalizations and deaths. The study notes that innovative drug manufacturers reinvest roughly one-third of their revenues into research and development.
According to Dr. Wayne Winegarden, director of PRI's Center for Medical Economics and Innovation and the brief's author, "GLP-1s are among the most promising medical breakthroughs in decades," but allowing unauthorized manufacturers to mass market knockoffs "creates significant patient safety risks and undermines trust in the healthcare system." The FDA has raised concerns including improper storage, dosing errors, questionable sourcing of active pharmaceutical ingredients, and misleading advertising practices. Federal regulators stepped up enforcement in February 2026, when the FDA restricted GLP-1 active pharmaceutical ingredients from being used in unapproved compounded drugs and sent warning letters to 30 telehealth companies over illegal sales and misleading marketing. The U.S. Department of Health and Human Services recently referred telehealth company Hims & Hers to the Department of Justice to investigate potential violations of federal drug law.
The brief argues that compounded drugs—which aren't FDA-approved and whose safety or effectiveness isn't verified before patient use—can meet individual patient needs when approved drugs aren't suitable or available, but large-scale knockoff marketing crosses a line. The experimental weight loss drug Reatrutide is being marketed even before the FDA review and approval process has completed, the study notes. Because innovative drug makers pour roughly a third of revenues back into discovering new treatments, the financial hit from unauthorized competitors directly reduces the pool of money available for tomorrow's cures. Winegarden concludes that "patients deserve affordable access to innovative medicines, but the answer is not eroding patent protections or tolerating large-scale unauthorized GLP-1 knockoffs." Instead, the solution is healthcare payment reform that empowers patients, increases competition, lowers costs, and preserves the incentives to develop the next generation of cures.